GRN

Across TCGA pan-cancer cohorts, GRN mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GRN data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GRN mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GRN expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where GRN mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.307	0.508	<.001	60	view →
CCRCC	OS	Median	All	0.755	0.937	.001	37	view →
LSCC	DFS	Median	II,III,IV	0.963	0.855	.022	10	view →
GBM	DFS	Median	All	0.664	0.769	.023	7	view →
LUAD	OS	Tertile	All	0.680	0.886	.037	3	view →
HNSC	OS	Median	III,IV	0.599	0.777	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GRN–PDAC (DFS)

Open the PDAC breakdown →